Tickers

1. Composite Trajectory Verdict

Given COLL's acquisition-driven growth model in specialty pharma, the income statement matters most for assessing whether revenue growth translates to operating leverage, though the balance sheet is critical for tracking leverage from debt-financed acquisitions.

Composite Trajectory: Mixed

Revenue is growing across annual and interim periods (FY2025 +23.6% YoY to $780.6M; Q2 2026 +6.3% YoY to $199.9M; 6M 2026 +7.6% YoY to $393.4M), but GAAP profitability is deteriorating sharply: FY2025 net income fell 9.1% YoY to $62.9M despite higher revenue; Q2 2026 swung to a $15.1M net loss from $12.0M net income; 6M 2026 swung to a $0.6M net loss from $14.4M net income. Operating cash flow grew strongly in FY2025 (+60.7% to $329.3M) but flattened YTD 2026 (+0.5% to $128.4M). The balance sheet shows significantly increased leverage post-Azstarys: term debt rose to $852.8M at June 30, 2026 from $571.1M at Dec 31, 2025, while cash and marketable securities fell to $129.5M from $386.7M. Revenue growth and operating cash flow generation are improving; GAAP earnings, operating margin, and balance sheet leverage are deteriorating.

2. Red Flags

• GAAP net income declined 9.1% YoY in FY2025 ($62.9M vs $69.2M) despite 23.6% revenue growth, driven by SG&A up 35.4% ($284.8M vs $210.4M) and intangible amortization up 34.2% ($221.9M vs $165.3M) (10-K 2025-12-31, Consolidated Statements of Operations)
• Q2 2026 GAAP net loss of $15.1M vs $12.0M net income in Q2 2025; operating income collapsed 89.5% to $3.7M from $35.1M, primarily from $23.3M Azstarys acquisition-related expenses and executive transition costs (10-Q 2026-06-30, Condensed Statements of Operations; MD&A)
• 6M 2026 GAAP net loss of $0.6M vs $14.4M net income in 6M 2025; operating income down 39.1% to $34.6M from $56.8M (10-Q 2026-06-30, Condensed Statements of Operations)
• Term debt principal increased $281.7M in six months to $852.8M at June 30, 2026 from $571.1M at Dec 31, 2025, funded by $300M delayed draw for Azstarys acquisition (10-Q 2026-06-30, Condensed Balance Sheets; MD&A)
• Cash and marketable securities dropped to $129.5M at June 30, 2026 from $386.7M at Dec 31, 2025, a 66.5% decline (10-Q 2026-06-30, Condensed Balance Sheets; Condensed Statements of Cash Flows)
• Current ratio deteriorated to 1.03x at June 30, 2026 ($608.0M current assets vs $589.9M current liabilities) from 1.57x at Dec 31, 2025 ($691.4M vs $440.0M) (10-Q 2026-06-30, Condensed Balance Sheets)
• Accrued rebates, returns and discounts jumped 27.8% to $406.9M at June 30, 2026 from $318.3M at Dec 31, 2025, partly from $81.3M assumed in Azstarys acquisition (10-Q 2026-06-30, Condensed Balance Sheets; Note 3)
• Deferred tax liability of $41.0M appeared at June 30, 2026 (zero at Dec 31, 2025) from Azstarys acquisition (10-Q 2026-06-30, Condensed Balance Sheets; Note 4)
• Contingent consideration liability of $38.5M recorded at June 30, 2026 for Azstarys milestones (zero previously) (10-Q 2026-06-30, Condensed Balance Sheets; Note 4)
• Non-GAAP adjusted EBITDA and adjusted net income show positive trends but exclude recurring acquisition-related costs ($28.4M in 6M 2026), executive transition costs, and step-up inventory amortization that appear in multiple periods (10-Q 2026-06-30, MD&A Non-GAAP Measures)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

GAAP profitability has deteriorated materially across comparable periods. FY2025 net income fell 9.1% to $62.9M from $69.2M despite 23.6% revenue growth, as operating expenses rose 36.7% to $283.6M (driven by full-year Ironshore integration: SG&A +35.4%, amortization +34.2%). Q2 2026 swung to a $15.1M net loss from $12.0M net income YoY; operating income dropped 89.5% to $3.7M from $35.1M, with SG&A surging 44.7% to $106.6M including $23.3M Azstarys acquisition costs. 6M 2026 net loss of $0.6M vs $14.4M net income YoY; operating income down 39.1% to $34.6M from $56.8M. Gross margin compressed: FY2025 59.3% vs 59.8%; Q2 2026 55.2% vs 57.7%; 6M 2026 57.8% vs 56.2%. The filing attributes operating expense increases to acquisition integration (Ironshore full year in 2025, Azstarys in 2026), sales force expansion, and executive transition costs.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Operating cash flow generation improved strongly annually but flattened recently. FY2025 operating cash flow rose 60.7% to $329.3M from $205.0M, driven by higher cash earnings and working capital normalization post-Ironshore. However, 6M 2026 operating cash flow was essentially flat at $128.4M vs $127.8M in 6M 2025, despite 7.6% revenue growth, as the filing notes "a decrease in cash flow from operating results, which reflects operating earnings after adjustment for non-cash items." Investing cash flow swung to -$501.0M in 6M 2026 from -$12.6M in 6M 2025 due to $655.4M Azstarys acquisition (net of cash acquired). Financing cash flow swung to +$270.7M in 6M 2026 from -$73.6M in 6M 2025, driven by $299.5M delayed draw term loan proceeds for Azstarys. Net cash decreased $101.8M in 6M 2026 vs a $41.6M increase in 6M 2025. Cash paid for interest was $34.4M in 6M 2026 vs $35.5M in 6M 2025; cash paid for taxes rose to $37.5M from $32.3M.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Leverage and liquidity have weakened significantly following the Azstarys acquisition. Total term debt (current + long-term) increased 49.3% to $852.8M at June 30, 2026 from $571.1M at Dec 31, 2025. Cash and marketable securities fell 66.5% to $129.5M from $386.7M. Total liabilities rose 34.6% to $1.824B from $1.355B. Shareholders' equity increased only modestly to $311.9M from $301.7M. The current ratio deteriorated to 1.03x ($608.0M current assets vs $589.9M current liabilities) from 1.57x. Intangible assets jumped 77.2% to $1.186B from $669.5M and goodwill rose 30.3% to $190.2M from $145.9M, reflecting $635M Azstarys intangible and $44.3M goodwill. Accrued rebates/returns/discounts rose 27.8% to $406.9M. Deferred tax liability of $41.0M and contingent consideration of $38.5M appeared new. The 2025 Credit Facility provides $300M delayed draw (fully drawn) and $100M revolver (fully available), but near-term term loan principal payments of $55M are due within 12 months.

6. Data Gaps

• Q1 2026 standalone quarterly GAAP income statement (10-Q 2026-03-31 provided but not parsed for quarterly P&L detail in this analysis)
• Q3 2025 and Q4 2025 standalone quarterly GAAP income statements for full 2025 quarterly trend
• FY2023 full income statement (only summary figures in 10-K for three-year comparison)
• Segment-level operating profit or contribution margin by product (not disclosed)
• Organic revenue growth rate excluding acquisitions (not separately quantified)
• Free cash flow definition and calculation (not provided; capex minimal but acquisition-driven investing dominates)
• Debt maturity schedule beyond "next 12 months" principal amounts (not detailed in provided excerpts)
• Interest rate on 2025 Term Loan and delayed draw term loan (not explicitly stated in provided text)
• Detailed breakdown of $23.3M Q2 2026 acquisition-related expenses beyond summary categories